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Introduction: In our present single-center pilot study, umbilical cord (UC)–derived mesenchymal stem cells (MSCs)
had a good safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE). The
present multicenter clinical trial was undertaken to assess the safety and efficacy of allogeneic UC MSC transplantation
(MSCT) in patients with active and refractory SLE.
Methods: Forty patients with active SLE were recruited from four clinical centers in China. Allogeneic UC MSCs were
infused intravenously on days 0 and 7. The primary endpoints were safety profiles. The secondary endpoints included
major clinical response (MCR), partial clinical response (PCR) and relapse. Clinical indices, including Systemic Lupus
Erythematosus Disease Activity Index (SLEDAI) score, British Isles Lupus Assessment Group (BILAG) score and renal
functional indices, were also taken into account.
Results: The overall survival rate was 92.5% (37 of 40 patients). UC-MSCT was well tolerated, and no transplantation-related
adverse events were observed. Thirteen and eleven patients achieved MCR (13 of 40, 32.5%) and PCR (11 of 40,
27.5%), respectively, during 12 months of follow up. Three and four patients experienced disease relapse at 9 months
(12.5%) and 12 months (16.7%) of follow-up, respectively, after a prior clinical response. SLEDAI scores significantly
decreased at 3, 6, 9 and 12 months follow-up. Total BILAG scores markedly decreased at 3 months and continued to
decrease at subsequent follow-up visits. BILAG scores for renal, hematopoietic and cutaneous systems significantly
improved. Among those patients with lupus nephritis, 24-hour proteinuria declined after transplantation, with
statistically differences at 9 and 12 months. Serum creatinine and urea nitrogen decreased to the lowest level at
6 months, but these values slightly increased at 9 and 12 months in seven relapse cases. In addition, serum levels
of albumin and complement 3 increased after MSCT, peaked at 6 months and then slightly declined by the 9- and
12-month follow-up examinations. Serum antinuclear antibody and anti-double-stranded DNA antibody decreased
after MSCT, with statistically significant differences at 3-month follow-up examinations.
Conclusion: UC-MSCT results in satisfactory clinical response in SLE patients. However, in our present study, several
patients experienced disease relapse after 6 months, indicating the necessity to repeat MSCT after 6 months.
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Systemic lupus erythematosus (SLE) is a common and po-
tentially fatal autoimmune disease characterized by auto-
antibodies associated with multiorgan injury, including
the renal, cardiovascular, neural, musculoskeletal and cu-
taneous systems [1]. Although disease severity and organ
involvement vary significantly among SLE patients, abnor-
malities of T and B lymphocytes are universal [2-4]. A dee-
per understanding of the underlying pathology is crucial
to the development of optimal therapies for the resto-
ration of immune homeostasis [5].
In addition to conventional immunosuppressive therap-
ies, such as cyclophosphamide (CYC) and mycophenolate
mofetil (MMF), several new strategies have been devel-
oped to target specific activation pathways relevant to SLE
pathogenesis [6]. For instance, B-cell-depleting therapies
using the monoclonal antibodies rituximab and the B-
lymphocyte stimulator (BLyS) inhibitor belimumab have
been beneficial in a specific subpopulation of lupus pa-
tients [7,8]. Recently, hematopoietic stem cell trans-
plantation (HSCT) has been reported to improve disease
activity in treatment-refractory SLE [9] and in reverse
organ dysfunction in several animal models [10], but the
rates of relapse and treatment-related toxicity are high, as
are the rates for the development of a secondary auto-
immune disorder [11].
Mesenchymal stem cells (MSCs) have been widely stu-
died as an alternative cell source for their ability to dif-
ferentiate into multiple mesenchymal lineages, including
bone, fat and cartilage [12]. Recent studies have indicated
that these pluripotent cells can also differentiate into
endoderm and neuroectoderm lineages, including neu-
rons, hepatocytes and cardiocytes [13-15]. MSCs have
been found to possess immunomodulatory effects on vari-
ous activated immune cells, such as T cells, B cells, natural
killer cells and dendritic cells [16-18]. Additionally, MSCs
are able to escape alloantigen recognition because of their
low immunogenicity and accompanying lack of expression
of costimuatory molecules. These properties make MSCs
promising candidate cells for preventing rejection in organ
transplantation and treatment of autoimmune disease.
In recent years, we have published pilot single-center
clinical studies in which we have reported the safety and
efficacy of allogeneic bone marrow– or umbilical cord
(UC)–derived MSCs in treating drug-resistant SLE pa-
tients, and the clinical results have been encouraging
[19,20]. However, we had some relapsed cases during
long-term follow-up [21]; thus, we found it is necessary
to conduct a multicenter clinical study to further con-
firm the efficacy of MSC-based treatment and to explore
the best effective time to initiate it in lupus patients. In
our present multicenter clinical study, we found that
intravenous UC MSC transplantation (MSCT) was safe
and observed no transplantation-related adverse events.UC MSC treatment resulted in clinical disease remission
and systemic amelioration in lupus patients who are
refractory to other. However, some patients had disease
relapses after 6 months; therefore, we believe that a re-
peated MSC infusion is feasible and necessary after
6 months to avoid disease relapse.
Methods
Patients
From December 2009 to August 2011, 40 SLE patients
ranging in age from 17 to 54 years were enrolled into our
trial. Informed consent was obtained from each patient
and donor. All enrolled patients met at least four of the
eleven American College of Rheumatology criteria for
SLE. The eligibility criteria included treatment-refractory
and active disease, as well as a Systemic Lupus Erythema-
tosus Disease Activity Index (SLEDAI) score of more than
8 or at least one British Isles Lupus Assessment Group
(BILAG) grade A or at least two BILAG grade B manifes-
tations. Refractory to treatment was defined as lack of re-
sponse to treatment with monthly intravenous pulse CYC
(500 to 750 mg/m2) for at least 6 months [22,23], or lack
of response to treatment with oral MMF (≥ 1,000 mg/day)
[24] or leflunomide (20 mg/day) for at least 3 months, or
continued daily doses of at least 20 mg of prednisone
(Pred) or its equivalent. Patients were excluded from the
study if they had uncontrolled infection, New York Heart
Association functional classification III or IV, failure of
one of the vital organs or were pregnant or lactating. Ac-
tive lupus nephritis (LN) was defined by meeting at least
one of the following criteria: (1) laboratory tests docu-
menting active LN three consecutive times: decrease in
renal function (serum creatinine > 1.2 mg/dl), increase in
proteinuria (> 1.0 g of protein excretion in a 24-hour urine
specimen), deterioration in microscopic hematuria (> 10
red blood cells per high-power field) or the presence of
cellular casts; or (2) renal biopsy documenting LN accord-
ing to the International Society of Nephrology/Renal Path-
ology Society 2003 classification system criteria for active
or active/chronic LN in renal biopsy class III, class IV-S or
class IV-G, class V, class III + class V or class IV + class V
[25]. The study was conducted in compliance with current
good clinical practice (GCP) standards and in accordance
with the principles set forth under the 1989 Declaration of
Helsinki. The protocol was approved by the Ethics Com-
mittee at The Drum Tower Hospital of Nanjing University
Medical School, The Affiliated Hospital of Jiangsu
University, Jiangsu Provincial People’s Hospital and Subei
People’s Hospital of Jiangsu Province.
Study design
UC MSCs were prepared by the Stem Cell Center of
Jiangsu Province, which is the National Stem Cell Institute
in China and a member of the International Society for
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by the American Association of Blood Banks. Fresh UCs
were obtained from informed healthy mothers in a local
maternity hospital after normal deliveries. The UCs were
rinsed twice in phosphate-buffered saline in penicillin and
streptomycin, and the cord blood was removed during this
process. The washed UCs were cut into 1-mm2 pieces and
floated in low-glucose Dulbecco’s modified Eagle’s me-
dium containing 10% fetal bovine serum. The pieces of
UC were subsequently incubated at 37°C in a humidified
atmosphere consisting of 5% CO2. Nonadherent cells were
removed by washing. The medium was replaced every
3 days after the initial plating. When well-developed col-
onies of fibroblast-like cells appeared after about 10 days,
the cells were trypsinized and passaged into a new flask
for further expansion.
Cell viability was determined by trypan blue testing.
The culture supernatant was analyzed for pathogenic
microorganisms by direct cultivation analysis. Super-
natant levels of alanine aminotransferase and endo-
toxins for each cell preparation were determined using
an automatic biochemistry analyzer and by tachypleus
amebocyte lysate analysis, respectively. In addition,
supernatant virus indexes were determined by enzyme-
linked immunosorbent assay. Cell surface labeling mar-
kers, including CD29, CD73, CD90, CD105, CD45,
CD34, CD14, CD79 and human leukocyte antigen major
histocompatibility complex class II molecule, DR haplo-
type (HLA-DR), as well as their isotype controls, were
all purchased from eBioscience (San Diego, CA, USA),
and cell phenotypes were studied by flow cytometric
analysis (FCM). We used good manufacturing practice
conditions and clinical grade reagents to prepare the
cells, and the protocol was conducted in compliance
with GCP standards. One million cells per kilogram of
body weight were administered by intravenous infusion
on days 0 and 7.
Endpoints
Each patient returned for follow-up at 1, 3, 6, 9 and
12 months after MSCT. Evaluations performed at these
follow-up visits included a physical examination, deter-
mination of SLEDAI score, BILAG analysis, serologic
studies and evaluation of organ function. Adverse events
and their severity were assessed and recorded throughout
the study. Primary efficacy endpoints were major clinical
response (MCR) and partial clinical response (PCR) as-
sessed during the 12-month study period. A MCR was de-
fined as achieving BILAG C scores or better in all organs
at 6 months without experiencing a severe flare, which
was defined, in turn, as one new domain with a BILAG A
score or two new domains with BILAG B scores from
MSC infusion and maintenance of this response through-
out the 12-month study period. A PCR was defined as (1)BILAG C scores or better and maintenance of this
response without a new BILAG A or B score within
3 months; and (2) having no more than one organ with a
BILAG B score at 6 months without achieving at least one
new BILAG A or B score throughout the 12-month study
period [26]. No clinical response was defined as failure to
meet the definition of a MCR or PCR. Clinical relapse was
defined as development of at least one new domain with a
BILAG A or B score after a previous MCR or PCR. Se-
condary efficacy endpoints included SLEDAI score, lupus
serologic changes, systemic evaluations such as renal func-
tional indexes, and hematological involvement. Trans-
plantation-related mortality included all deaths associated
with UC MSCT, except those related to recurrence of
underlying disease. The investigators assessed and re-
corded adverse events and their severity throughout the
study.
After UC MSCT, the doses of steroids as well as im-
munosuppressive drugs were tapered according to the
amelioration of disease conditions. The dose of Pred was
tapered by 5 to 10 mg every 2 weeks during the first
month following transplantation for responders. If the
clinical index was not improved or if disease activity had
not declined, which was defined as nonresponse, the
drug dose was not tapered or new drugs might be
chosen. When relapse occurred, the dose of Pred or im-
munosuppressive drug would be added or new drugs
would be given. This protocol is uniformly adhered to at
each center, and the trial was monitored by the third
party (The Stem Cell Center of Jiangsu Province).
Statistical analysis
Data were analyzed as of the last data collection in
August 2011. Patients were censored at the time of
death or last follow-up. We used Fisher’s exact test to
compare the distribution of categorical variables. Pair-
wise comparisons of pre- and post-MSCT variables were
analyzed by paired t-test analysis using SPSS version
13.0 statistical software (IBM SPSS, Chicago, IL, USA).
The comparisons of clinical responses between patients
with or without CYC treatment were analyzed by χ2 test.
The BILAG index for different organ systems was used
to assess response, and scores were converted to nu-
meric values (A = 9, B = 3, C = 1, D = 0 and E = 0) to en-
able evaluation [27,28]. All P values were two-sided, and
P < 0.05 was considered statistically significant.
Results
Participant characteristics
Forty patients, including thirty-eight females and two
males, were enrolled in this trial. Twenty-six patients were
enrolled from The Department of Rheumatology, the
Affiliated Drum Tower Hospital of Nanjing University
Medical School, Nanjing, China, 6, 5 and 3 patients were
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Affiliated Hospital of Jiangsu University, Zhenjiang, China,
the Department of Rheumatology, Subei People’s Hospital
of Jiangsu Province, Yangzhou, China, and the De-
partment of Rheumatology, Jiangsu Provincial People’s
Hospital, Nanjing, China, respectively. The mean disease
duration was 90.9 months, ranging from 15 to 264 months.
Baseline demographics and clinical manifestations for
each patient are shown in Table 1. Thirty-nine patients
(39/40, 97.5%) underwent two times of UC MSC infusions
with an interval of one week, and one patient (1/40, 2.5%)
was exempted from the second MSC infusion because of
uncontrolled disease progression.Umbilical cord mesenchymal stem cell characteristics
All the infused UC MSCs were derived from passages 2
to 4, with rigorous purification and quality control. The
cell viability of purified MSCs was greater than 92%. The
culture supernatant was negative for pathogenic micro-
organisms, including aerobic and anaerobic bacteria, as
well as for hepatitis B surface antigen, hepatitis B core
antibody, hepatitis C virus antibody, HIV antibodies I
and II, cytomegalovirus immunoglobulin M and syphilis
antibody. FCM analysis showed CD29, CD73, CD90 and
CD105 expression greater than 95% in parallel with
CD45, CD34, CD14, CD79 and HLA-DR expression less
than 2%. In addition, levels of alanine aminotransferase
and endotoxins in the supernatants of each cell pre-
paration were strictly controlled within 40 IU/L and 5
endotoxin units, respectively. The capacity of MSCs to
differentiate into adipogenic and osteogenic lineages was
also assayed.Safety
After 12 months, the overall survival rate was 92.5% (37 of
40 patients). Three patients died as a result of uncon-
trolled disease activity and organ failure. One patient had
active lupus with malar rash, arthralgia, uncontrolled
hypertension and rapid deterioration of renal function,
hypoproteinemia and severe proteinuria. She died 7 days
after the first MSC infusion as a result of uncontrolled
progressive disease and acute heart failure. Another pa-
tient had a lupus relapse 8 months after MSC infusion,
with pulmonary hypertension, and died as a result of
right-sided heart failure 256 days after MSCT. The third
patient also had disease relapse 6 months after MSCT,
with steroid-resistant thrombocytopenia and uncontrolled
septicemia, and ultimately died due to respiratory failure
192 days after MSC infusion. Two patients had moderate
herpesvirus infection 291 and 135 days after MSC treat-
ment, respectively, and one patient had tuberculosis infec-
tion at 326 days. All the infection adverse events were
treated by conventional therapies. Adverse events werenot considered to be possibly related to UC MSCT. All
the adverse events are listed in Table 2.
Clinical outcomes
Clinical responses
Thirteen and eleven patients achieved MCR (13 of 40
patients, 32.5%) and PCR (11 of 40 patients, 27.5%), re-
spectively, during 12 months of follow-up. In total, 16
patients had no clinical response (16 of 40 patients,
40%). Three and four patients, respectively, experienced
disease relapse at 9 months (12.5%) and 12 months
(16.7%) of follow-up after a prior MCR or PCR. Twenty-
six patients received CYC as basal treatment, and the
other fourteen patients did not. However, we did not
observe any difference in the rate of clinical remission
between the two groups (P > 0.05 by χ2 test).
Disease activity assessment
Lupus disease activity, as defined by SLEDAI score, signifi-
cantly decreased after MSCT (mean ± SD values = 10.83 ±
4.63 at baseline, 8.55 ± 3.99 at 1 month, 7.43 ± 3.93 at
3 months, 6.30 ± 3.63 at 6 months, 6.40 ± 3.84 at 9 months
and 6.48 ± 3.52 at 12 months; all P < 0.01 versus baseline
levels) (Figure 1A). Total BILAG score was markedly ame-
liorated after UC MSC infusion (mean ± SD values =
10.78 ± 6.09 at baseline, 5.35 ± 4.48 at 1 month, 5.28 ± 4.71
at 3 months, 4.23 ± 4.43 at 6 months, 3.85 ± 4.73 at
9 months and 3.55 ± 4.33 at 12 months; all P < 0.001 ver-
sus baseline levels) (Figure 1B).
Serology changes
Serum albumin levels improved shortly after UC MSC
infusions, were normal at the 1-month follow-up visit
and remained normal during the succeeding 9 months
until the 12-month follow-up visit, when they declined
(mean ± SD values = 3.17 ± 0.75 g/dl at baseline, 3.70 ±
0.58 g/dl at 1 month, 3.80 ± 0.67 g/dl at 3 months, 3.84 ±
0.63 g/dl at 6 months, 3.89 ± 0.64 g/dl at 9 months and
3.67 ± 0.78 g/dl at 12 months; all P < 0.05 versus baseline
levels) (Figure 2A). Serum complement 3 improved with
statistical significance found at 6 months (Figure 2B).
Serum complement 4 levels showed no obvious changes
after MSC treatment in those patients. We observed
that serum anti-double-stranded DNA antibody levels
decreased after MSCT with statistically significant dif-
ferences found at the 6- and 12-month follow-up visits
(mean ± SD values = 710.83 ± 814.05 U/ml at baseline,
526.78 ± 666.7 U/ml at 1 month, 590.41 ± 702.99 U/ml at
3 months, 492.67 ± 615.15 U/ml at 6 months, 513.58 ±
378.6 U/ml at 9 months and 212.62 ± 244.77 U/ml at
12 months; n = 16), along with decreased serum antinu-
clear antibody (mean ± SD values = 5.77 ± 2.32 at baseline,
5.40 ± 2.08 at 1 month, 5.24 ± 2.66 at 3 months, 4.85 ±









Total cumulative dose of IS Clinical outcomes
after MSCT
Clinical manifestations
1/46 40 17 12 CYC 0.8 gm/mo × 28mo PCR LN, A, C, V, H, ANA+, anti-dsDNA+
2/37 41 12 12 CYC 0.8 gm/mo × 35mo PCR A, LN, V, ANA+, anti-dsDNA+, H
3/21 50 11 9 MMF 1.5 gm/d × 31mo NR V, LN, C, anti-SM+
4/28 98 9 9 CYC 0.8 gm/mo × 10mo, CYC 0.8 gm/mo combined with
MMF 1.0 gm/d × 28mo (discontinue), LEF 20 mg/d × 31 mo
MCR V, A, alopecia, LN, C, ANA+, anti-dsDNA+
5/26 120 12 8 MMF 2.0 gm/d × 50mo (discontinue), CYC 0.8 gm/mo × 20mo NR V, A, LN, ANA+, anti-dsDNA+
6/23 15 14 19 CYC 0.8 gm/mo × 15mo, LEF 20 mg/d × 10mo NR V, A, F, LN, P, ANA+, anti-dsDNA+
7/20 62 12 18 MMF 1.5 gm/d × 34mo (discontinued), CYC 0.8 gm/mo × 24mo PCR A, F, LN, C, P, ANA+
8/43 26 34 20 CYC 0.8 gm/mo × 10mo (discontinued), LEF 20 mg/d × 10mo PCR→ R C, V, LN, A, seizures, ANA+
9/36 97 10 26 CYC 0.8 gm/mo × 29mo MCR→ R C, V, A, LN, P, ANA+
10/39 60 10 7 CYC 0.8 gm/mo × 25mo (discontinued), LEF 20 mg/d × 30mo PCR LN, A, V, ANA+, anti-SM+
11/22 40 8 16 CYC 0.8 gm/mo × 25mo NR LN, C, P, ANA+, anti-dsDNA+
12/20 50 14 13 CYC 0.8 gm/mo × 15mo (discontinued), VCR 1 mg/week ×
4times (discontinued)
NR A, severe thrombocytopenia, V, F, ANA+,
anti-dsDNA+, anti-SM+
13/17 75 7 6 MMF 1.5 gm/d × 13mo (discontinued), LEF 20 mg/d × 30 mo NR Severe thrombocytopenia, LN, A, ANA+,
anti-dsDNA+
14/21 39 12 11 CYC 0.8 gm/mo × 17mo NR LN, F, P, A, anti-dsDNA+
15/36 60 10 7 LEF 20 mg/d × 20 mo (discontinued), CYC 0.8 gm/mo × 37mo MCR LN, V, P, A, ANA+, anti-SM+
16/16 49 11 15 CYC 0.8 gm/mo × 17mo (discontinued), LEF 20 mg/d × 20mo NR LN, A, V, ANA+
17/44 145 4 8 CYC 0.8 gm/mo × 64mo NR LN, A, V, C, ANA+
18/44 85 8 9 CYC 0.8 gm/mo × 40mo PCR A, LN, F, ANA+, anti-dsDNA+
19/29 86 10 5 CYC 0.8 gm/mo × 24mo PCR→ R LN, A, P, F, ANA+, anti-dsDNA+
20/54 264 8 4 CYC 0.8 gm/mo × 36mo (discontinued), MMF 1.5 gm/d × 12 mo,
then MMF 1.0 gm/d × 28 mo
MCR LN, A, V, C, ANA+
21/36 121 13 13 CYC 0.8 gm/mo × 25mo, LEF 20 mg/d × 40mo PCR→ R LN, A, V, C
22/40 24 12 8 CYC 0.8 gm/mo × 18mo NR F, V, LN, C, ANA+
23/35 25 14 24 CYC 0.8 gm/mo × 21mo NR F, A, V, LN, P
24/27 48 12 7 LEF 20 mg/d × 4mo (discontinued), CYC 0.8 gm/mo × 40mo MCR LN, F, A, P, ANA+, anti-SM+
25/30 102 10 7 MMF 2.0 gm/d × 6mo, then tapered to 1.5 gm/d × 36 mo,
LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 59 mo
PCR V, A, LN, ANA+, anti-dsDNA+
26/31 62 8 3 MMF 1.5 gm/d × 8mo, then tapered to 1.0 gm/d × 50 mo,
LEF 20 mg/d × 19 mo
MCR→ R LN, V, P, ANA+, anti-dsDNA+
27/51 108 13 29 CYC 0.8 gm/mo × 41mo, CsA 150 mg/d × 30 mo NR LN, V, A, C, seizures
















Table 1 Clinical manifestation for each patient at baselinea (n = 40)* (Continued)
29/45 102 10 9 CYC 1.2 gm/mo × 22mo NR A, V, LN, ANA+, anti-dsDNA+
30/33 62 10 9 CYC 0.8 gm/mo × 21mo, LEF 20 mg/d × 12 mo MCR LN, A, P, C
31/32 156 14 12 CYC 0.8 gm/mo × 36mo (discontinued), MMF 1.5 gm/d × 6 mo,
then tapered to 1.0 gm/d × 56 mo
MCR→ R LN, A, C, P
32/53 146 12 10 CYC 0.8 gm/mo × 24mo, then tapered to 0.6 gm/mo × 42mo,
LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 40 mo
NR LN, A, C, anti-dsDNA+
33/30 157 8 7 CYC 0.8 gm/mo × 16mo (discontinued) NR V, LN, A, C, H
34/35 123 10 9 CYC 0.8 gm/mo × 18mo, LEF 20 mg/d × 22 mo NR LN, A, H, C, ANA+
35/33 216 10 3 CYC 0.8 gm/mo × 26mo PCR F, LN, V, C, A
36/39 99 5 7 CYC 0.8 gm/mo × 14mo MCR LN, C, V, anti-dsDNA+
37/35 109 6 6 LEF 20 mg/d × 34 mo PCR→ R LN, C, H, ANA+
38/31 160 9 7 LEF 20 mg/d × 13 mo (discontinued), CYC 0.8 gm/mo × 35mo MCR LN, C, V, A
39/50 108 10 12 CYC 0.8 gm/mo × 14mo MCR F, LN, A, V, C
40/35 96 8 8 CYC 0.8 gm/mo × 28mo (discontinued), LEF 20 mg/d × 7mo MCR LN, V, P, C, ANA+
aA, Arthralgia; ANA, Antinuclear antibody; Anti-dsDNA, anti-double-stranded DNA antibody; C, Cytopenia; F, Febrile; H, Hypocomplementemia; IS, Immunosuppressive drug; LN, Lupus nephritis; MCR, Major clinical re-
sponse; NR, Nonresponse; P, Polyserositis; PCR, Partial clinical response; R, Relapse; V, Vasculitis; VCR, Vincristine. Patients’ clinical manifestations were recorded within 1 week before umbilical cord mesenchymal stem
cell transplantation. Total patient population = 40. Patients 1 to 26 were enrolled from the Department of Rheumatology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China. Patients 27
to 32 were enrolled from the Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China. Patients 33 to 37 were enrolled from the Department of Rheumatology, Subei People’s Hospital of
















Table 2 Adverse events by umbilical cord mesenchymal stem cell treatment within 12 monthsa
Patient Adverse events Severity Time (days) Related to MSCT
2 Herpesvirus infection AE 291 No relation
3 Herpesvirus infection AE 135 No relation
3 Herpesvirus infection AE 187 No relation
9 Death SAE 7 No relation
12 Tuberculosis infection AE 326 No relation
14 Death SAE 256 No relation
27 Death SAE 192 No relation
aAE, Adverse event; MSCT, Mesenchymal stem cell treatment; SAE, Severe adverse event.
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at 12 months) (Figures 2C and D).
Organ function improvement
Thirty-eight (95%) of forty patients had active LN (renal
BILAG A or B score) at baseline, but their renal BILAG
scores decreased significantly after two UC MSC infusions
(Figure 3A). Twenty-four-hour proteinuria levels decreased
significantly after UC MSC treatment (mean ± SD values =
2.24 ± 1.43 g at baseline, 2.13 ± 1.35 g at 1 month, 1.91 ±
1.20 g at 3 months, 1.65 ± 1.11 g at 6 months, 1.24 ± 1.09 g
at 9 months and 1.41 ± 1.33 g at 12 months; P < 0.05 at
9- and 12-month follow-up visits) (Figure 3B). Renal func-
tion index, as assessed by serum creatinine and blood urea
nitrogen levels, also decreased, and both showed statis-
tically significant differences at the 6-month follow-up visit
(Figures 3C and D), but they increased at the 12-month
follow-up visit. Twenty-five (62.5%) and twenty-eight
(70%) of the forty patients had hematopoietic and cutane-
ous system involvement, respectively, at baseline. The
BILAG score for the two systems also ameliorated after
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A
Figure 1 Graphs illustrate changes in clinical status before and after u
clinical status from before umbilical cord mesenchymal stem cell transplan
Erythematosus Disease Activity Index (SLEDAI) score (A) and total British Isl
MSCT. ***P < 0.001 versus before MSCT. Error bars mean SD values.Therapy schedule after umbilical cord mesenchymal stem
cell infusion
The dose of Pred was tapered from 5 to 10 mg every
2 weeks during the first month following transplantation,
according to clinical status and laboratory indicators of
disease amelioration. During the 12-month follow-up
visits, 30 (81.08%) of 37 patients underwent steroid taper-
ing, and, though 19 (54.29%) of 35 patients underwent im-
munosuppressant tapering after MSCT, two patients were
excluded because they had not been taking immunosup-
pressive drugs at baseline (Table 3).
Discussion
MSCs are multipotent, nonhematopoietic progenitor cells
that are currently being explored as a promising new
treatment for tissue regeneration. Although their im-
munomodulatory properties are not yet completely under-
stood, their low immunogenic potential, together with
their effects on immune responses, make them a promi-
sing therapeutic tool for the treatment of patients with se-
vere and refractory autoimmune diseases. MSCs have



























*** *** *** *** ***
mbilical cord mesenchymal stem cell transplantation. Changes in
tation (MSCT) and afterward were assessed based on Systemic Lupus
es Lupus Assessment Group (BILAG) score (B). **P < 0.01 versus before
BA
DC
Figure 2 Graphs illustrate improvement after allogeneic umbilical cord mesenchymal stem cell transplantation. Improved levels serum
albumin (A) and complement 3 (C3) (B) in lupus patients refractory to other treatments. Serum levels of anti-double-stranded DNA
(anti-sDNA) antibody (C) and antinuclear antibody (ANA) (D) decreased after MSC infusions. *P < 0.05 versus before mesenchymal stem cell
transplantation (MSCT). Error bars mean SD values.
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chemic cardiomyopathy [31,32] and autoimmune diseases
such as systemic sclerosis [33], inflammatory bowel dis-
ease [34,35], dermatomyositis/polymyositis [36], rheuma-
toid arthritis [37], Sjögren’s syndrome [38] and type 1 or
type 2 diabetes mellitus [39,40].
To date, to the best of our knowledge, only limited clin-
ical investigations of MSC treatment in lupus patients
have been conducted. We previously conducted a small-
scale, short-term study of intravenous delivery of UC
MSCs [19]. Recently, a larger-scale study of 87 lupus cases
and long-term follow-up of 4 years explored the clinical
responses to allogeneic MSCT [21]. However, we did not
have the evidence of a multicenter study to further con-
firm the results. Our present multicenter study has sub-
stantiated the clinical safety and efficacy of UC MSCT for
the treatment of lupus patients, as determined previously
in single-center studies. Sixty percent of patients achieved
MCR or PCR after 12 months of follow-up, and another
40% had no clinical response. Intravenous infusion of UC
MSCs is a safe practice with treatment efficacy in im-
proving renal function and serologic indices. In addition
to a significant decline of disease activity as assessed by
SLEDAI and BILAG scores, UC MSC infusion amelio-
rated systemic manifestations in hematopoietic and cuta-
neous systems.We previously compared the clinical efficacy of single
and double MSC infusions in lupus patients, and the re-
sults showed that the treatment efficacy was comparable
between the two groups [41]. In our present multicenter
study, 39 of the 40 enrolled patients received double UC
MSC infusions with a 1-week interval. At 12 months of
follow-up, we found that the clinical response rate and
safety profile were comparable. The results further indi-
cate that a single infusion is enough in clinical treatment
to be effective.
However, the role of MSCs in vivo is not permanent. In
the present study, 12.5% and 16.7% of patients had disease
relapses at 9 and 12 months of follow-up, respectively,
after a prior MCR or PCR. Serologic indices, such as
serum albumin and complement 3 levels, reverted slightly
toward baseline, concomitantly with relapsed renal func-
tion indices, on the basis of serum creatinine and blood
urea nitrogen levels. On the basis of the safety profile of
MSC infusion in clinical applications, our data suggest the
necessity of repeating MSC infusions after 6 months in re-
fractory lupus patients.
MSCs can be isolated from many tissues, including
bone marrow, UC, UC blood, placenta or adipose tissue.
Bone marrow–derived MSCs, both autologous and allo-
geneic, are widely used in clinical applications. However,




Figure 3 Graphs illustrate marked improvement in renal system after umbilical cord mesenchymal stem cell transplantation. (A) British
Isles Lupus Assessment Group (BILAG) score improved over time. Twenty-four hours after umbilical cord mesenchymal stem cell transplantation
(MSCT), declines were observed in proteinuria (B), serum creatinine (C) and blood urea nitrogen (BUN) (D). BILAG scores for the hematopoietic
(E) and cutaneous (F) systems were ameliorated after MSCT. *P < 0.05 versus before MSCT. **P < 0.01 versus before MSCT. Error bars mean SD values.
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http://arthritis-research.com/content/16/2/R79MSCs from bone marrow are difficult to obtain, have
ethical issues and are easily contaminated. Moreover, au-
tologous bone marrow–derived MSCs are functionally
abnormal in some disorders such as lupus [42,43], rheu-
matoid arthritis [44] and systemic sclerosis [45], which
may limit their clinical application. UCs fall off after de-
livery, but they are rich in MSCs. UC MSCs have many
advantages over bone marrow MSCs, including easy
access, less possibility of contamination and no ethical
problems. Furthermore, UC MSCs, in contrast to bone
marrow MSCs, do not express tumor-associated fibro-
blast phenotypes and therefore have no opportunity togrow solid tumors [46]. Moreover, UC MSCs have a
higher rate of gene expression related to cell adhesion,
morphogenesis, angiogenesis and neurogenesis than UC
blood–derived MSCs do [47], and they can accumulate
more mineralized matrix than placenta-derived MSCs
[48], indicating that UC MSCs may be used as an opti-
mal cell therapy option.
The present study has some limitations. First, 95% of
the patients had active LN at the time of study entry,
but we cannot provide the pathologic data of the present
enrolled patients. Therefore, we do not know whether
MSCs can indeed ameliorate renal pathology, aside from
Table 3 Treatments used before and after umbilical cord mesenchymal stem cell transplantation in each patienta
Patient Baseline 1 month 3 months 6 months 12 months
1 Pred 5 mg/d Pred 5 mg/d, Pred 5 mg/d Pred 5mg/d Pred 5mg/d
CYC 0.8 g/mo CYC 0.8 g/mo, CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
LEF 20 mg/d LEF 20 mg/d, LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
2 Pred 30 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
3 Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 15 mg/d Pred 15 mg/d
MMF 1.5 g/d MMF 1.5 g/d MMF 1.5 g/d MMF 1.5 g/d MMF 1.0 g/d
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
4 Pred 10 mg/d Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 10 mg/d LEF 10 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 200 mg/d
5 Pred 10 mg/d Pred 10 mg/d Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
6 Pred 20 mg/d Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
Triptolide 60 mg/d Triptolide 60 mg/d
7 Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo
HCQ 300 mg/d HCQ 300 mg/d HCQ 300 mg/d HCQ 300 mg/d HCQ 300 mg/d
8 Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 30 mg/d Pred 10 mg/d
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 300 mg/d
9 Pred 40 mg/d Pred 25 mg/d Pred 15 mg/d Pred 10 mg/d /
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
10 Pred 10 mg/d Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d
LEF 20 mg/d LEF 20 mg/d LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
11 Pred 20 mg/d Pred 20 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.4 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
12 Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
13 Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
14 Pred 15 mg/d / / / /
CYC 0.8 g/mo
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Table 3 Treatments used before and after umbilical cord mesenchymal stem cell transplantation in each patienta
(Continued)
15 Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo, CYC0.8 g/mo, CYC 0.4 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 300 mg/d HCQ 300 mg/d HCQ 300 mg/d
16 Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 20 mg/d
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
17 Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/45 d CYC 0.8 g/45d CYC 0.4 g/mo
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
18 Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
19 Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 15 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo CYC 0.8 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
20 Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d Pred 5 mg/d
MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d MMF 0.5 g/d
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
21 Pred 7.5 mg/d Pred 7.5 mg/d Pred 5 mg/d Pred 15 mg/d Pred 15 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 200 mg/d















23 Pred 45 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 200 mg/d
24 Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 5 mg/d Pred 5 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo
25 Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d
MMF 1.5 g/d MMF 1.5 g/d MMF 1.5 g/d MMF 1.0 g/d MMF 1.0 g/d
LEF 10 mg/d LEF 10 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d
HCQ 400 mg/d HCQ 400 mg/d
26 Pred 20 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 20 mg/d
MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
27 Pred 50 mg/d Pred 30 mg/d Pred 15 mg/d MP 80 mg/d /
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/d × 3 d
CsA 150 mg/d CsA 150 mg/d CsA 150 mg/d γ-globulin 20 g × 3 d
28 Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 5 mg/d Pred 5 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
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Table 3 Treatments used before and after umbilical cord mesenchymal stem cell transplantation in each patienta
(Continued)
29 Pred 30 mg/d Pred 25 mg/d Pred 20 mg/d Pred 10 mg/d Pred 5 mg/d
CYC 1.2 g/mo CYC 1.2 g/mo CYC 1.2 g/mo CYC 1.2 g/mo CYC 0.8 g/mo
Triptolide 60 mg/d Triptolide 60 mg/d
30 Pred 25 mg/d Pred 20 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC0.8 g/mo CYC0.8 g/mo CYC0.6 g/mo
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 10 mg/d
31 Pred 30 mg/d Pred 25 mg/d Pred 25 mg/d Pred 30 mg/d Pred 15 mg/d
MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d MMF 1.0 g/d
32 Pred 25 mg/d Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d
CYC 0.6 g/mo CYC 0.6 g/mo CYC 0.6 g/mo CYC 0.6 g/mo CYC 0.6 g/mo
LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 200 mg/d
33 Pred 25 mg/d Pred 15 mg/d Pred 15 mg/d Pred 35 mg/d Pred 35 mg/d
34 Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
LEF 20 mg/d LEF 20 mg/d LEF 10 mg/d LEF 10 mg/d LEF 10 mg/d
35 Pred 20 mg/d, Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo
36 Pred 25 mg/d Pred 15 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo CYC 0.6 g/mo
HCQ 400 mg/d HCQ 400 mg/d HCQ 400 mg/d HCQ 300 mg/d HCQ 300 mg/d
37 Pred 20 mg/d Pred 15 mg/d Pred 15 mg/d Pred 15 mg/d Pred 20 mg/d,
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
38 Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d Pred 7.5 mg/d Pred 7.5 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.6 g/mo
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
39 Pred 20 mg/d Pred 15 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d
CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo CYC 0.8 g/mo
HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d HCQ 200 mg/d
40 Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d Pred 10 mg/d Pred 5 mg/d
LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d LEF 20 mg/d
aCsA Cyclosporine A; CYC, Cyclophosphamide; HCQ, Hydroxychloroquine; LEF, Leflunomide; MMF, Mycophenolate mofetil; MP, methylprednisone; MSCT, Mesenchymal
stem cell transplantation; Pred, Prednisone; UC MSC, Umbilical cord–derived mesenchymal stem cells. Patients 1 to 26 were enrolled from the Department of
Rheumatology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China. Patients 27 to 32 were enrolled from the Department of Rheumatology,
Affiliated Hospital of Jiangsu University, Zhenjiang, China. Patients 33 to 37 were enrolled from the Department of Rheumatology, Subei People’s Hospital of Jiangsu
Province, Yangzhou, China. Patients 38 to 40 were enrolled from the Department of Rheumatology, Jiangsu Provincial People’s Hospital, Nanjing, China.
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not a randomized controlled trial. It lacks a group of pa-
tients who received conventional therapies, but not com-
bined with allogeneic MSC infusion. Therefore, the
current data provide evidence only that allogeneic MSCT
could induce renal remission on the basis of other drugs
taken by patients enrolled in this study. Third, because of
the differences in patients’ conditions at the time of enroll-
ment, we cannot be sure of the uniformity and standards
for quality control between the different centers ordifferent patients. We will consider performing a multi-
center randomized controlled study in China to assess the
safety and efficacy of MSCT in LN patients to compare
the clinical safety and efficacy of combined steroid/MSC
treatment and combined steroid/traditional immunosup-
pressive drug therapy such as CYC. In the forthcoming
trial, repeated renal biopsy will be designed to further de-
termine whether MSCT can alleviate renal pathology in
LN patients. In addition, we will try to ensure uniformity
among the enrolled patients for quality control.
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Our multicenter clinical study illustrates the safety and
efficacy of systemic administration of UC MSCs in SLE
patients. Moreover, a repeated MSC infusion is feasible
and necessary after 6 months to avoid disease relapse.
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